

APIS Breast Cancer Subtyping Kit

The APIS Breast Cancer Subtyping Kit is a highly reproducible, RT-gPCR-based kit for detecting mRNA expression of standard breast cancer biomarkers (HER2, ER, PR, Ki67) and novel proliferative biomarkers from core-needle biopsy (CNB) or resected formalin-fixed paraffin embedded (FFPE) breast tumour tissue. Receptor tyrosine-protein kinase erbB-2 (HER2), oestrogen receptor (ER), progesterone receptor (PR), and marker of proliferation (Ki67) biomarkers play a key role in breast cancer.

The kit also includes a novel four-gene proliferative signature that comprises four markers (MKI67, CCNA2, KIF23, and PCNA) associated with proliferation. These markers are expressed throughout all cell cycle stages, providing a more precise representation of tumour proliferation.



Advantages of the APIS Breast Cancer Subtyping Kit



Reproducible and precise detection of HER2, ER, PR & Ki67 mRNA expression



Requires only 10µm CNB or resected FFPE sections with as little as 20% tumour content




Novel four-gene proliferative signature provides a more precise representation of tumour proliferation



Only 2 hours from PCR setup to result generation

APIS Breast Cancer Subtyping Kit

Delivering precise results for standard biomarkers and a novel proliferative signature in **less than 5 hours** when processing 10 samples.



APIS[®]

 10µm FFPE tissue section (tumour content ≥ 20%)

Sample Preparation

Recommended RNA Extraction & Normalisation

- Use of RNeasy® DSP FFPE Tissue Kit
- Fluorometric RNA Quantification

APIS Breast Cancer Subtyping Kit Setup

- Master mix prep and plate set up
- Up to 10 samples per plate

RT-qPCR Reaction

Recommended for use with QuantStudio™ 5 Dx Instrument

 Analysis and Results Interpretation
Analysis and target relative expression can be reported as Delta Ct (△Ct) values.

The APIS Breast Cancer Subtyping Kit contains an internal control (IC), a synthetic RNA sequence, which monitors for assay set up, reagent performance and interfering substances. Positive and Negative Controls (PC and NTC) which monitor run validity and reagent performance are also supplied with the kit.


A Comprehensive Molecular Profile for Breast Cancer

The APIS Breast Cancer Subtyping Kit uses One Step RT-qPCR with dye-linked oligonucleotides to detect sequence amplification. To selectively amplify the mRNA sequence, at least one of the oligonucleotides used to generate the amplicon is spanning an exon-exon boundary. The probe binds to the target sequence between the primers.



APIS Breast Cancer Subtyping Kit Performance

Comparison of APIS Breast Cancer Subtyping Kit expression measure (Δ Ct) with IHC% nuclei staining for each target. A strong correlation between IHC% staining and the APIS Breast Cancer Subtyping Kit can be observed.



Y axis; APIS RNA gene expression (△Ct value) with assays cut-off (dashed line) indicating positive/negative calling. Cut off values valid only when analysis performed using QS5™Dx instrument. X axis; IHC positive nuclei (%).

Ordering Information

| Product Name | Test Type | Kit Size | Catalogue Number Code | Price |
|----------------------------------|-----------|---------------------------------------|----------------------------------|------------------------|
| APIS Breast Cancer Subtyping Kit | RUO | 24 Samples in duplicate plus controls | 00402 (distributed by Biocartis) | Available upon request |
| APIS Breast Cancer Subtyping Kit | RUO | 24 Samples in duplicate plus controls | 00403 (distributed by APIS) | Available upon request |

Please visit the product web page for the list of countries that Biocartis distributes the APIS Breast Cancer Subtyping Kit. APIS is the distributor for all other countries.

All scientific and analytical information in this brochure comes from the APIS Breast Cancer Subtyping Kit Instructions for Use ART0049.

The APIS Breast Cancer Subtyping Kit is intended for Research Use Only (RUO). Not for use in medical or clinical diagnostic procedures.



To order the APIS Breast Cancer Subtyping Kit or to learn more about how our assay can elevate your breast cancer research capabilities, please contact your local distributor using the details below.

UK sales agent:



LINK Medical Solutions

Phone: +44 (0) 203 1373 193 Address: 85 Great Portland St, First Floor, London, W1W 7LT Email: info@linkmedicalsolutions.com

International distributor:



Biocartis

Phone: +32 (0) 15 632 600 Address: Generaal De Wittelaan 11B, 2800 Mechelen, Belgium Email: info@biocartis.com